Abeona Therapeutics is a clinical-stage biopharmaceutical company that develops gene and cell therapies for life-threatening rare genetic diseases. It was incorporated in 1974 and is headquartered in New York, New York.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Abeona Therapeutics news
13.05.2022
Abeona Therapeutics' GAAP loss for 3 months of 2022 was $20.791 million, up 29.9% from $16.002 million in the previous year. Revenues were $346,000. The company did not generate revenues a year earlier.
Source: 
investors.abeonatherapeutics.com
investors.abeonatherapeutics.com
31.03.2022
Abeona Therapeutics' GAAP loss for 2021 was $84.936 million, up 0.8% from $84.234 million in the prior year. Revenue declined 70% to $3 million from $10 million a year earlier.
Source: investors.abeonatherapeutics.com
investors.abeonatherapeutics.com
15.11.2021
Abeona Therapeutics' GAAP loss for 9M 2021 was $38.253 million, down 44.1% from $68.406 million in the prior year. The company did not generate revenue. A year earlier the figure was $7 million.
Source: investors.abeonatherapeutics.com
investors.abeonatherapeutics.com
29.07.2021
Abeona Therapeutics' GAAP net income for 6 months of 2021 was $31.209 million, down 49% from $61.169 million in the prior year.
Source: investors.abeonatherapeutics.com
investors.abeonatherapeutics.com
General information
| Company name | Abeona Therapeutics |
|---|---|
| Tags | #pharmacy, #biotechnology |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 1330 Avenue of the Americas 33rd Floor New York, NY 10019 United States |
| Mailing address | 1330 Avenue of the Americas 33rd Floor New York, NY 10019 United States |
| Website | investors.abeonatherapeutics.com |
| Information disclosure | www.sec.gov |
English (US) 